期刊文献+

聚乙二醇干扰素α-2a联合利巴韦林治疗代偿期丙肝后肝硬化疗效观察 被引量:16

Efficacy of peg interferon α-2a in combination with ribavirin in treatment of with hepatitis C cirrhosis patients
收藏 分享 导出
摘要 目的 观察聚乙二醇干扰素α-2a联合利巴韦林治疗代偿期丙肝后肝硬化临床疗效.方法 21例慢性丙型肝炎后肝硬化患者(治疗组),采用聚乙二醇干扰素α-2a 135~180 μ.g皮下注射,每周1次,利巴韦林片600~1000 mg/d,疗程48周,随访24周;20例慢性丙型肝炎患者(对照组),聚乙二醇干扰素α-2a135~180 g皮下注射,每周1次,利巴韦林600~1000 mg/d,疗程48周,随访24周.比较两组快速病毒学应答(RVR)率、早期病毒学应答(EVR)率、持续病毒学应答(SVR)率,观察不良反应.结果 治疗组和对照组RVR、EVR、ETVR无显著性差异、治疗组SVR较对照组低(P<0.05),治疗组中骨髓抑制及贫血发生率更高(P<0.05),流感样症状,脱发,胃肠道反应等不良反应两组间差异无统计学意义.结论 丙肝后肝硬化患者,临床使用135 μg聚乙二醇干扰素α-2a及个体化、小剂量利巴韦林较为安全,可获得较好的早期应答,持续病毒学应答率较慢性肝炎为低,治疗过程应密切观察血常规及肝肾功能并处理不良反应. Objective To study the clinical efficacy of PEG Interferon α-2a combined with ribavirin in treatment of with hepatitis C cirrhosis patients.Methods 21 patients with chronic hepatitis C cirrhosis (treated group),were treated with peg-IFNα-2a 135 - 180 μg subcutaneously,i week,ribavirin tablets 800 -1000 mg/d,48 weeks of treatment and follow-up 24 weeks,20 patients with Chronic hepatitis C (control group),were treated with peg-IFNα-2a 135 - 180 μg subcutaneously,1 week,ribavirin tablets 600 - 1000 mg/d,48 weeks of treatment,follow-up 24 weeks,comparison of rapid virological response ( RVR ) rates,early virologic response (EVR) rate,sustained virologic response (SVR) rate,adverse reactions was observed.Results The differences of RVR,EVR,ETVR in two groups is not significant,but SVR in treatment group was lower ( P 〈 0.05 ),and has a higher incidence bone marrow suppression and anemia ( P 〈 0.05 ).Flu-like symptoms,hair loss,gastrointestinal reactions and other adverse reactions was no significant difference between the two groups.Conclusion The use of 135 μg peg-IFNα-2a and individual in low-dose ribavirin hepatitis C patients with cirrhosis is more security,could get a good early response,but sustained virologic response (SVR) rates is lower than hepatitis C patients.Blood,liver and kidney function should be closely observed during treatment process.
作者 刘光伟 王春芳 赵文霞 马素平 LIU Guang-wei(First Affiliated Hospital of Henan College of TCM, Hepatology Department, Zhengzhou 450014, China) WANG Chun-fang(First Affiliated Hospital of Henan College of TCM, Hepatology Department, Zhengzhou 450014, China) ZHAO Wen-xia(First Affiliated Hospital of Henan College of TCM, Hepatology Department, Zhengzhou 450014, China) MA Su-ping(First Affiliated Hospital of Henan College of TCM, Hepatology Department, Zhengzhou 450014, China)
出处 《中华实验和临床病毒学杂志》 CAS CSCD 北大核心 2011年第6期 477-479,共3页 Chinese Journal of Experimental and Clinical Virology
关键词 干扰素Α 肝硬化 利巴韦林 Interferon-alpha Liver cirrhosis Ribavirin
  • 相关文献

参考文献5

二级参考文献32

共引文献225

同被引文献102

引证文献16

二级引证文献26

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈
新型冠状病毒肺炎防控与诊疗专栏